Loading clinical trials...

An Observational Study on The Health Related Quality of Life in Patients With Chronic Lymphocytic Leukaemia | Clinical Trials | Clareo Health

COMPLETED

An Observational Study on The Health Related Quality of Life in Patients With Chronic Lymphocytic Leukaemia

Utility Measurement Study for Patients With Chronic Lymphocytic Leukaemia

NCT01395615•Hoffmann-La Roche

View on ClinicalTrials.gov

Summary

This observational study will assess the health related quality of life (HQRL) profiles of patients with chronic lymphocytic leukaemia. Using health assessment questionnaires, data will be collected from patients currently receiving therapy and from those who have finished therapy and have undergone an assessment of treatment.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Adult patients, \>/= 18 years of age
•Patients with chronic lymphocytic leukaemia
•Patients receiving 1st line therapy
•Patients receiving 2nd line therapy. This will include patients who previously have responded well to 1st line therapy (relapse was \>12 months after finishing the 1st line therapy) and are receiving the same therapy again
•Within the past three months, patients whose treatment has been stopped after 2-3 cycles of 1st or 2nd line therapy and who have not received any further therapies
•Patients receiving their 3rd, 4th, 5th or 6th cycle of 1st or 2nd line therapy
•Patients who have completed therapy, are considered stable and are between 3-12 months post therapy
•Eastern Cooperative Oncology Group (ECOG) performance status 0-1

Exclusion Criteria

•Clinically significant disorder (other than chronic lymphocytic leukaemia and chronic lymphocytic comorbidities) or any other condition, including alcohol or drug abuse, which may interfere with study participation or affect study conclusions
•Mental disability or significant mental illness, legal incapacity or limited legal capacity
•Current high degree of comorbid burden that might affect the accuracy of the quality of life data

Locations (5)

Bournemouth, United Kingdom

Leeds, United Kingdom

London, United Kingdom

Taunton, United Kingdom

Key Dates

Start Date

October 1, 2008

Primary Completion Date

October 1, 2009

Completion Date

October 1, 2009

Last Updated

November 2, 2016

Enrollment

ACTUAL participants

Conditions

Lymphocytic Leukemia, Chronic

Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia

NCT02242942

Lymphocytic Leukemia, Chronic

View study

TERMINATEDPHASE4

A Study to Compare Mabthera (Rituximab), Fludarabine and Cyclophosphamide to Mabthera and Chlorambucil in Participants With Chronic Lymphocytic Leukemia and Unfavorable Somatic Status

NCT01283386

Lymphocytic Leukemia, Chronic

View study

COMPLETEDPHASE1

A Study to Compare Subcutaneous Versus Intravenous MabThera (Rituximab) in Combination With Chemotherapy in Patients With Chronic Lymphocytic Leukemia

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 2, 2016Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

An Observational Study on The Health Related Quality of Life in Patients With Chronic Lymphocytic Leukaemia

Inclusion Criteria

Exclusion Criteria

Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia

A Study to Compare Mabthera (Rituximab), Fludarabine and Cyclophosphamide to Mabthera and Chlorambucil in Participants With Chronic Lymphocytic Leukemia and Unfavorable Somatic Status

A Study to Compare Subcutaneous Versus Intravenous MabThera (Rituximab) in Combination With Chemotherapy in Patients With Chronic Lymphocytic Leukemia

Rituximab in Combination With Fludarabine and Cyclophosphamide in Patients With Chronic Lymphocytic Leukemia